Why Is H. B. Fuller (FUL) Down 11% Since Last Earnings Report?
H. B. Fuller (FUL) reported earnings 30 days ago. What's next for the stock?
FUL or NVZMY: Which Is the Better Value Stock Right Now?
Investors interested in Chemical - Specialty stocks are likely familiar with H. B. Fuller (FUL) and Novozymes A/S (NVZMY).
Why H. B. Fuller (FUL) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should Value Investors Buy H. B. Fuller (FUL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
FUL Stock Is Riding Medical, Aerospace and Pricing Trends
FUL is tapping medical, aerospace and pricing trends to support margins, but volume weakness still clouds its path to stronger growth.
Is FUL Stock a Buy Now or a Value Trap for Cautious Investors?
FUL trades near the low end of its five-year valuation range as improving earnings meet volume, inflation and leverage risks tied to its medical-market expansion.
H.B. Fuller Stock Outlook Hinges on Margins, Mix and M&A
FUL's outlook rests on pricing, margins and portfolio reshaping as medical expansion and M&A aim to offset uneven demand across key end markets.
FUL vs. PPG: Which Stock Is the Better Value Option?
Investors interested in stocks from the Chemical - Specialty sector have probably already heard of H. B. Fuller (FUL) and PPG Industries (PPG).
H.B. Fuller: Overreaction, Or Proof Of Slowdown
H.B. Fuller is rated a "buy" with a conservative $80/share price target, reflecting improved fundamentals and recent M&A. FUL's recent results validate earnings recovery: near-6% revenue growth, ~20% AEPS improvement, double-digit EBITDA gains, and record operating cash flow. The AMS acquisition is expected to drive margin expansion, higher-quality revenue, and meaningful revenue and cost synergies, supporting long-term profitability.
H.B. Fuller Company (FUL) Q2 2026 Earnings Call Transcript
H.B. Fuller Company (FUL) Q2 2026 Earnings Call Transcript
H.B. Fuller to buy UK's Advanced Medical Solutions for $942 million
U.S.-based adhesives maker H.B. Fuller will buy Advanced Medical Solutions Group in a cash deal that values the British medical supplier at about £715 million ($942.1 million) including debt, the companies said on Thursday.
H. B. Fuller (FUL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for H. B. Fuller (FUL) give insight into how the company performed in the quarter ended May 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
